@article{a3f1144add984311af1a93506cd1d85a,
title = "A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy",
abstract = "The combination of irinotecan and bevacizumab has shown efficacy in the treatment of recurrent glioblastoma multiforme (GBM). A prospective, phase II study of 85 patients with various recurrent brain tumors was carried out. Primary endpoints were progression free survival (PFS) and response rate.",
keywords = "Adult, Aged, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Brain Neoplasms, Camptothecin, Disease Progression, Female, Glioblastoma, Humans, Male, Middle Aged, Neoplasm Grading, Neoplasm Recurrence, Local, Prognosis, Prospective Studies, Standard of Care, Survival Rate, Young Adult",
author = "S{\o}ren M{\o}ller and Kirsten Grunnet and Steinbj{\o}rn Hansen and Schultz, {Henrik Pagh} and Mats Holmberg and Morten Mau-S{\o}rensen and Poulsen, {Hans S} and Ulrik Lassen",
year = "2012",
doi = "10.3109/0284186X.2012.681063",
language = "English",
volume = "51",
pages = "797--804",
journal = "Acta Oncologica",
issn = "0284-186X",
publisher = "Informa Healthcare",
number = "6",
}